莉芙敏改善妇科恶性肿瘤患者术后绝经综合征的临床研究
|
摘要
目的:观察莉芙敏改善妇科恶性肿瘤患者术后的绝经症状的疗效;对骨代谢的影响;评估患者体内血雌二醇、黄体生成素、卵泡刺激素、血脂的水平;观察与药物有关的不良反应。
方法:收集大连市妇产医院自2010年3月-2011年3月的因妇科恶性肿瘤切除双侧卵巢并且术前未绝经的患者,其中23名患者同意莉芙敏治疗绝经症状。患者年龄在43岁至54岁之间,其中子宫内膜癌12例,Ⅰ期8例、Ⅱ期2例、Ⅲ期2例;卵巢癌5例,Ⅰ期1例、Ⅱ期2例,Ⅲ期2例;宫颈癌2例,Ⅰ期2例(近绝经期故同时切除了双侧附件);卵巢交界性肿瘤2例,ⅠC期1例,Ⅱ期1例;乳癌术后2例(外科医生建议切除双侧卵巢,更改药物治疗方式)。患者自术后出现绝经症状且改良Kupperman评分》15时应用莉芙敏(黑升麻根茎的异丙醇提取物)40mg每天,治疗12周。改良kupperman评分包括潮热出汗、失眠、焦虑、抑郁等共13项,程度评分为0～3分,加权分:潮热出汗为4分,感觉异常、失眠、焦虑、泌尿系症状、性生活为2分,其余皆为1分。加权分乘以程度评分即为该项得分,总分为每项相加的总和。用药期间在0W、4W、8W、12W通过记录改良的Kupperman评分评价其疗效,改良的Kupperman评分<15分,认为有效的,计算治疗有效的患者的百分率;在用药0W及12W检测血清碱性磷酸酶、高密度脂蛋白、低密度脂蛋白、血清总胆固醇、血清甘油三酯、雌二醇、黄体生成素、卵泡雌激素。检测用药前后血常规及肝肾功的水平,记录患者出现的不良反应。
结果:本实验可以观察到Kupperman评分由用药前的21.70±5降到用药12周后的8.65±4.97,有效率为85.7%;潮热出汗由6.78±3.06降到用药12周后的2.09±2.37 ;失眠4±1.6降到用药12周后的2.17±1.34;焦虑抑郁6.13±1.84降到用药12周后的3.39±1.16 ,用药前后的差异均有统计学意义的;患者体内的E2由用药前的16.17±3.93pg/ml到用药12周后15.75±3.80 pg/ml;FSH由65.23±16.24mIU/ml到用药12周后的66.14±17.29mIU/ml ;LH有用药前39.12±10.24mIU/ml到用药12周后的40.95±11.12mIU/ml;差异均无统计学意义(p>0.05)。碱性磷酸酶由48±10.93IU/L升高到用药12周后的57±17.80IU/L ,差异有统计学意义(p<0.05)。高密度脂蛋白HDL-C由1.37±0.35mmol/l升高到用药12周后的1.68±0.61mmol/l;低密度脂蛋白由3.18±0.86mmol/l降低到用药12周后的2.67±0.79mmol/l,用药前后有统计学差异;血清甘油三酯由1.41±0.9mmol/l到用药12周后的1.38±0.61mmol/l;血清总胆固醇CHOL由5.27±0.9mmol/l到用药12周后的5.23±0.83mmol/l,用药前后无统计学差异。血常规及血生化检验没有发生有临床意义的改变,不良反应出现4例胃肠道反应。
结论:莉芙敏有效的改善恶性肿瘤患者术后的绝经症状,尤其是对潮热出汗、焦虑抑郁、失眠有明显的效果;不改变体内雌二醇(E2)、卵泡刺激素(FSH)、黄体生成素(LH)的水平;升高碱性磷酸酶;不影响血清总胆固醇、甘油三酯,增加高密度脂蛋白,减低低密度脂蛋白。不良反应少,且轻微。
Objective: Remifemin improve gynecological malignant tumor postoperative patients of menopause syndrome; The influence of bone metabolism; Evaluate the patients' estradiol, luteinizing hormone follicle stimulating hormone, lipids. Observation and drug related adverse reactions.
Methods:Collect Dalian Maternity Hospitals from March 2010 to March 2011 by gynecologic malignant tumor resection of bilateral ovarian and preoperative not postmenopausal patients, 23 patients agree with Remifemin treatment postmenopausal symptoms. The patients between 43 to 54, 12 cases of endometrial carcinoma ,Ⅰperiod 8 cases,Ⅱperiod in 2 cases, 2 casesⅡperiod; Ovarian cancer in 5 patients, andⅠperiod 1 case ,in 2 casesⅡperiod ,2 casesⅡperiod; Cervical cancerⅠperiod in 2 cases, 2 cases (near menopause reason also removed the bilateral annex); borderline ovarian tumors in 2 casesⅠC period ,in 1 caseⅡperiod; 2 cases (postmastectomy breast surgeon suggest excision bilateral ovarian, change medications).
Since the postoperatie patients with menopausal symptoms and improved Kupperman score》15 scores. Remifemin (an isopropanolic black cohosh extract) 40mg /d,treatment for 12 weeks. Improved kupperman score including hot perspire, insomnia, anxiety, depression, totaling 13 item, degree score of 0 ~ 3 points, weighted points: hot sweat is four points, cacesthesia、insomnia、anxiety、urinary tract symptoms、sex life weretwo points, the rest were for 1 minute. Weighted points for the multiply degree rating score, the total was the sum of the sum for each item. During the course of medication 0W 4W 8W and 12W by recording Kupperman score evaluatd its curative effect,( if improved Kupperman score < 15 points was effective), calculate the percentage of effective treatment for patients. For medication in 0W and12W detectd serum alkaline phosphatase, high-density lipoprotein cholesterol (hdl-c), low density lipoprotein, serum total cholesterol, serum triglyceride, estradiol, FSH, LH. Medication before and after detected blood routine and liver and kidney level, record patients experienced adverse reactions.
Result:This experiment can be observed the Kupperman score dreased from21.70±5 to 8.65±4.97 after 12 weeks treatment, effective power was 85.7%.The hot sweat was reduced from 6.78±3.06 to 2.09±2.37 12 weeks treatment;Insomnia was reduced from4±1.6to 2.17±1.34after 12 weeks treatment;Anxiety depressed 6.13±1.84 to 3.39±1.16 after 12 weeks treatment; There were statistically significant differences(p < 0.05).E2 was 16.17±3.93pg/ml to 15.75±3.80 pg/ml after 12 weeks treatment;FSH was 65.23±16.24 mIU/ml to 66.14±17.29mIU/ml after 12 weeks treatment;LH was 39.12±10.24mIU/ml to 40.95±11.12mIU/ml after 12 weeks treatment, There were no statistically significant difference (p > 0.05). Serum alkaline phosphatase was ascended from 48±10.93IU/L to57±17.80IU/L, difference was statistically significant (p < 0.05). HDL-C was ascended from 1.37±0.35mmol/lto1.68±0.61mmol/l after 12 weeks treatment; LDL-C was ascended from 3.18±0.86mmol/l to 2.67±0.79mmol/l after 12 weeks treatment, difference was statistically significant (p < 0.05).TGL was from1.41±0.9mmol/lto 1.38±0.61mmol/lafter 12 weeks treatment ; CHOL from 5.27±0.9mmol/l to 5.23±0.83mmol/lafter 12 weeks treatment, there were no statistically significant difference (p > 0.05). Routine blood and blood biochemistry examines not happened clinically meaningful change, adverse effects weae 4 cases of gastrointestinal reaction.
Conclusion: Remifemin was effective in relieving emotional symptoms,mainly hot flashes、insomnia and anxiety in patients,with no effect on E2、FSH、LH. Remifemin caused a slight but significant decrease of LDL-cholesterol,and increase of HDL-cholesterol, without affecting total cholesterol and triglycerdes. Fewer side effects, and light.
方法:收集大连市妇产医院自2010年3月-2011年3月的因妇科恶性肿瘤切除双侧卵巢并且术前未绝经的患者,其中23名患者同意莉芙敏治疗绝经症状。患者年龄在43岁至54岁之间,其中子宫内膜癌12例,Ⅰ期8例、Ⅱ期2例、Ⅲ期2例;卵巢癌5例,Ⅰ期1例、Ⅱ期2例,Ⅲ期2例;宫颈癌2例,Ⅰ期2例(近绝经期故同时切除了双侧附件);卵巢交界性肿瘤2例,ⅠC期1例,Ⅱ期1例;乳癌术后2例(外科医生建议切除双侧卵巢,更改药物治疗方式)。患者自术后出现绝经症状且改良Kupperman评分》15时应用莉芙敏(黑升麻根茎的异丙醇提取物)40mg每天,治疗12周。改良kupperman评分包括潮热出汗、失眠、焦虑、抑郁等共13项,程度评分为0～3分,加权分:潮热出汗为4分,感觉异常、失眠、焦虑、泌尿系症状、性生活为2分,其余皆为1分。加权分乘以程度评分即为该项得分,总分为每项相加的总和。用药期间在0W、4W、8W、12W通过记录改良的Kupperman评分评价其疗效,改良的Kupperman评分<15分,认为有效的,计算治疗有效的患者的百分率;在用药0W及12W检测血清碱性磷酸酶、高密度脂蛋白、低密度脂蛋白、血清总胆固醇、血清甘油三酯、雌二醇、黄体生成素、卵泡雌激素。检测用药前后血常规及肝肾功的水平,记录患者出现的不良反应。
结果:本实验可以观察到Kupperman评分由用药前的21.70±5降到用药12周后的8.65±4.97,有效率为85.7%;潮热出汗由6.78±3.06降到用药12周后的2.09±2.37 ;失眠4±1.6降到用药12周后的2.17±1.34;焦虑抑郁6.13±1.84降到用药12周后的3.39±1.16 ,用药前后的差异均有统计学意义的;患者体内的E2由用药前的16.17±3.93pg/ml到用药12周后15.75±3.80 pg/ml;FSH由65.23±16.24mIU/ml到用药12周后的66.14±17.29mIU/ml ;LH有用药前39.12±10.24mIU/ml到用药12周后的40.95±11.12mIU/ml;差异均无统计学意义(p>0.05)。碱性磷酸酶由48±10.93IU/L升高到用药12周后的57±17.80IU/L ,差异有统计学意义(p<0.05)。高密度脂蛋白HDL-C由1.37±0.35mmol/l升高到用药12周后的1.68±0.61mmol/l;低密度脂蛋白由3.18±0.86mmol/l降低到用药12周后的2.67±0.79mmol/l,用药前后有统计学差异;血清甘油三酯由1.41±0.9mmol/l到用药12周后的1.38±0.61mmol/l;血清总胆固醇CHOL由5.27±0.9mmol/l到用药12周后的5.23±0.83mmol/l,用药前后无统计学差异。血常规及血生化检验没有发生有临床意义的改变,不良反应出现4例胃肠道反应。
结论:莉芙敏有效的改善恶性肿瘤患者术后的绝经症状,尤其是对潮热出汗、焦虑抑郁、失眠有明显的效果;不改变体内雌二醇(E2)、卵泡刺激素(FSH)、黄体生成素(LH)的水平;升高碱性磷酸酶;不影响血清总胆固醇、甘油三酯,增加高密度脂蛋白,减低低密度脂蛋白。不良反应少,且轻微。
Objective: Remifemin improve gynecological malignant tumor postoperative patients of menopause syndrome; The influence of bone metabolism; Evaluate the patients' estradiol, luteinizing hormone follicle stimulating hormone, lipids. Observation and drug related adverse reactions.
Methods:Collect Dalian Maternity Hospitals from March 2010 to March 2011 by gynecologic malignant tumor resection of bilateral ovarian and preoperative not postmenopausal patients, 23 patients agree with Remifemin treatment postmenopausal symptoms. The patients between 43 to 54, 12 cases of endometrial carcinoma ,Ⅰperiod 8 cases,Ⅱperiod in 2 cases, 2 casesⅡperiod; Ovarian cancer in 5 patients, andⅠperiod 1 case ,in 2 casesⅡperiod ,2 casesⅡperiod; Cervical cancerⅠperiod in 2 cases, 2 cases (near menopause reason also removed the bilateral annex); borderline ovarian tumors in 2 casesⅠC period ,in 1 caseⅡperiod; 2 cases (postmastectomy breast surgeon suggest excision bilateral ovarian, change medications).
Since the postoperatie patients with menopausal symptoms and improved Kupperman score》15 scores. Remifemin (an isopropanolic black cohosh extract) 40mg /d,treatment for 12 weeks. Improved kupperman score including hot perspire, insomnia, anxiety, depression, totaling 13 item, degree score of 0 ~ 3 points, weighted points: hot sweat is four points, cacesthesia、insomnia、anxiety、urinary tract symptoms、sex life weretwo points, the rest were for 1 minute. Weighted points for the multiply degree rating score, the total was the sum of the sum for each item. During the course of medication 0W 4W 8W and 12W by recording Kupperman score evaluatd its curative effect,( if improved Kupperman score < 15 points was effective), calculate the percentage of effective treatment for patients. For medication in 0W and12W detectd serum alkaline phosphatase, high-density lipoprotein cholesterol (hdl-c), low density lipoprotein, serum total cholesterol, serum triglyceride, estradiol, FSH, LH. Medication before and after detected blood routine and liver and kidney level, record patients experienced adverse reactions.
Result:This experiment can be observed the Kupperman score dreased from21.70±5 to 8.65±4.97 after 12 weeks treatment, effective power was 85.7%.The hot sweat was reduced from 6.78±3.06 to 2.09±2.37 12 weeks treatment;Insomnia was reduced from4±1.6to 2.17±1.34after 12 weeks treatment;Anxiety depressed 6.13±1.84 to 3.39±1.16 after 12 weeks treatment; There were statistically significant differences(p < 0.05).E2 was 16.17±3.93pg/ml to 15.75±3.80 pg/ml after 12 weeks treatment;FSH was 65.23±16.24 mIU/ml to 66.14±17.29mIU/ml after 12 weeks treatment;LH was 39.12±10.24mIU/ml to 40.95±11.12mIU/ml after 12 weeks treatment, There were no statistically significant difference (p > 0.05). Serum alkaline phosphatase was ascended from 48±10.93IU/L to57±17.80IU/L, difference was statistically significant (p < 0.05). HDL-C was ascended from 1.37±0.35mmol/lto1.68±0.61mmol/l after 12 weeks treatment; LDL-C was ascended from 3.18±0.86mmol/l to 2.67±0.79mmol/l after 12 weeks treatment, difference was statistically significant (p < 0.05).TGL was from1.41±0.9mmol/lto 1.38±0.61mmol/lafter 12 weeks treatment ; CHOL from 5.27±0.9mmol/l to 5.23±0.83mmol/lafter 12 weeks treatment, there were no statistically significant difference (p > 0.05). Routine blood and blood biochemistry examines not happened clinically meaningful change, adverse effects weae 4 cases of gastrointestinal reaction.
Conclusion: Remifemin was effective in relieving emotional symptoms,mainly hot flashes、insomnia and anxiety in patients,with no effect on E2、FSH、LH. Remifemin caused a slight but significant decrease of LDL-cholesterol,and increase of HDL-cholesterol, without affecting total cholesterol and triglycerdes. Fewer side effects, and light.
引文
1.Mahady,G. B. IS black cohosh estrogenic? Nutr.Rev .2003,61,181-186
2.Cqrpenter,J.S.State of the science: hot flash and cancer .Part 2:management andfuture diretions.Oncol Nurs.Forum 2005,32,969-978.
3.Heckbert SR, Kaolan RC, Weiss NS, et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001;16:709.
4.Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605.
5.Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304.
6.Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologicalstudies of 52,705 women with breast cancer and 108,411 women without breast cancer.Lancet 1997;350:1047.
7.Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589.
8.Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.JAMA 2000;283:485.
9.Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of U.S. women. JAMA 2001;285:1460.
10.Blumenthal M, Busse WR, Goldberg A, et al., eds. Klein S, Rister RS, translators. German Commission E monographs: Therapeutic monographs on medicinal plants for human use. Austin, TX: American Botanical Council, 1998.
11.Schildge E. Beitrag zur Behandlung von pr?menstruellen und klimakterischen Verstimmungs-und Depressionszust?nden. Ringelh Biol Umsch 1964;19:18.
12.Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin HH. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol.2005;105:1074-83. [PMID: 15863547] 125I-labeled antipyrine
13.Nappia RE,Malavasi B,Brundu B,Facchinetti F,Efficacy of cimicifuga racemosa on climacteric complaint :a randomized study versus low-dose transdermal estradial.Gynecol Endocrinol 2005;20(1):30-35
14.Vermes G, Bánhidy F, Acs N.The effects of remifemin on subjective symptoms of menopause.Adv Ther 2005 Mar-Apr;22(2):148-54.
15.Molla MD, Hidalgo-Mora JJ, Soteras M G Phytotherapy as alternative to hormone replacement therapy. 2011 Jan 1;3:191-204.
16.wenpei Bai,Hans-Heinrich Henneicke-von Zepelin,Shuyu Wang,Shur.Efficacy and tolerability of a medicinal product congtaining an isopropanolic black cohosh extract in Chinese women with menoparusal symptoms: A randomized ,double blind ,parallel-controlled study versus tibolone Maturitas 58 (2007) 31-41
17.acobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739–45.
18.Liske E, H?nggi W, Henneicke-von Zepelin HH, Boblitz N, Wüstenberg P, Rahlfs VW。Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002 Mar;11(2):163-74.
19.Lehmann-Willenbrock E, Riedel HH. (Clinical and endocrinological examinations concerning therapy of climacteric symptoms following hysterectomy with remaining ovaries). Zentralbl Gynakol 1988;110:611.
20.Einer-Jensen N, Zhao J, Andersen KP, Kristoffersen K. Cimicifuga andMelbrosia lack oestrogenic effects in mice and rats. Maturitas 1996;25:149-153.Bibliographic Links Library Holdings
21.Freudenstein J, Dasenbrock C, Nisslein T. Lack of promotion of estrogen-dependentmammary gland tumors in vivo by an isopropanolic Cimicifuga racemosa extract.Cancer Res 2002;62:3448-3452. Bibliographic Links Library Holdings
22.Herbertson A,Aubin J E,Cell sorting enriches osteogenic populations in rat bone marrow stromal cell cultures[J] Bone,1997,21(6):491-500
23.Zepelin HH, Meden H, Kostev K, Schr?der-Bernhardi D, Stammwitz U, Becher HIsopropanolic black cohosh extract and recurrence-free survival after breast cancer. 2007 Mar;45(3):143-54.
24.Geller SE ,Studee L Botanical and dietary supplements for menopausal symptom: what work ,what dose not.J Womens Health 2005;14:634-649
25.Osmers R Kraft K.Phytotherapy in menopausal symptoms.Pharm Unserer Zeit 2004,33:384-381.
26.Liske E, H?nggi W, Henneicke-von Zepelin HH, Boblitz N, Wüstenberg P, Rahlfs VW。Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002 Mar;11(2):163-74.
27.O'Connor K, Belanger L, Marchand A, et al. Psychological distress andadaptational problems associated with discontinuation of benzodiazepines. AddictBehav. 1999;24:537-541.Bibliographic Links Library Holdings
28.Freudenstein J, Bodinet C. Influence of an isopropanolicaqueous extract of Cimicifuga racemosa rhizomaon the proliferation of MCF-7 cells. Abstractband: 23rd International LOF-Symposium on“Phyto-Oestrogens.”Workshop of the Society for MedicinalPlant Research, Gent, 1999.
29.Nesselhut T, Liske E. Pharmacological measures in postmenopausal women with an isopropanolic aqueousextract of Cimicifuga racemosa rhizoma. Abstract10th Annual Meeting NAMS, New York, September1999.
30.Kalantaridou SN,Davis SR,Calis LA. Hormone therapy in women.In: DiPiro JT,Talbert RL,Yee GC,et al.Pharmacotherapy:a pathophysiologic approach Sixth Edition.McGraw-Hill. 2005,PP: 1493 -1513.[25]Bai W,Henneicke-von Zepelin H-H,Wan
31.Gabort Vermes,MD.Ferenc banhidy,MD,PHD. Nandor Acs,MD,PHD.The effects of Remifemin on subjective symptoms of menopause Advance in therapy 2005;148-154
32.Nelson HD,Vesco KK,Haney E,Fu R ,Nedrow A, Miller J,Nicolaides C,Walker M,Humphery L (2006)Nonhormonal therapies for menopausal hot flash :systematic review and metanalysis .JAMA 295:2057-2071
33.Gerardo HM, Salvatore P. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer[ J ]. Maturitas, 2003, 44 (1) :59.
34.Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer[ J ]. J Clin Oncol, 2001, 19: 2739.
35.Pockaj BA, Loprinzi CL, Sloan JA, Novotny PJ, Barton DL,Hagenmaier A, Zhang H, Lambert GH, Reeser KA, Wisbey JA (2004) Pilot evaluation of black cohosh for the treatment of hotflashes in women. Cancer Invest 22:515–521
36.Burdette JE,Liu J,Chen SN. Black cohosh acts as a mixed competitiveligand and partial agonist of the serotonin receptor [J].Agricultural and Food Chemistry,2003,51( 19) : 5661 - 5670.
37.Maoz B, Shiber A, Lazer S, et al. Prevalence of psychological distress amongpostmenopausal women attending a menopausal clinic and the effect of hormone replacement therapy on their mental state. Menopause. 1994;1:137-141.
38.Amsterdam JD, Garcia-Espana F, Goodman D, et al. Breast enlargement duringchronic SSRI therapy. J Affect Disord. 1997;46:151-156.
39.O'Connor K, Belanger L, Marchand A, et al. Psychological distress andadaptational problems associated with discontinuation of benzodiazepines. AddictBehav. 1999;24:537-541. Bibliographic Links Library Holdings
40.Soares CN, Murray BJ.Sleep disorders in women: clinical evidence and treatment strategies. Psychiatr Clin North Am. 2006 Dec;29(4):1095-113; abstract xi.
41.Borrelli,F.Ernst,E. Black cohosh(cimicifuga racemosa)for menopausal symptom:a systematic review of its efficacy .Pharmacol Res.2008,58,8-14
42.Lehmann-Willenbrock E, Riedel HH. (Clinical and endocrinological examinations concerning therapy of climacteric symptoms following hysterectomy with remaining ovaries). Zentralbl Gynakol 1988;110:611.
43.Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. 2010 Mar;17(2):426-4
44.Hirschberg AL, Edlund M, Svane G, Azavedo E, Skoog L, von Schoultz B An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. 2007 Jan-Feb;14(1):89-96.
45.Freudenstein J, Dasenbrock C, Nisslein TLack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic Cimicifuga racemosa extract. Cancer Res. 2002 Jun 15;62(12):3448-52.
46.胡玉红不同术式对雌兔内分泌和骨代谢的影响中国比较医学杂志2007,7
47.徐丽丽杨乃龙体外诱导人骨髓间充质干细胞向成骨细胞的分化2008
48.刘忠厚.骨质疏松学[M].北京:科技出版社,1998.
49.陶敏芳等,双侧卵巢切除对绝经期妇女骨密度及身体成分的影响上海交通大学学报2010 (9)
50.Cos,P.et al.(2003)Phytoestrogens :recent developments.PLANTA Med.69,589-599
51.Schildge E. Beitrag zur Behandlung von pr?menstruellen und klimakterischen Verstimmungs-und Depressionszust?nden. Ringelh Biol Umsch 1964;19:18
52.Whiting PW,Clouston A,Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis [J]. Med J Aus,2002,177(8):432-435.
53.Naser B, Schnitker J, Minkin MJ, de Arriba SG, Nolte KU, Osmers R. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. 2011 Jan 11.
54.Pockaj B, Gallagher J, Loprinzi C, Stella P, Barton D, Sloan J, et al. Phase III double-blind, randomized, placebo-controlled clinical crossover trial of black cohosh in the management of hot flashes: NCCTG trial N01CC. J Clin Oncol 2006;24:2836–41.
55.acobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739–45.
56.Frei-Kleiner S, SchaffnerW, RahlfsVW, Bodmer C, Birkh¨auser M. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial.Maturitas 2005;51:397–404.
57.Bischoff M. Wechseljahre: Pflanzliche Alternativen auf dem Pr¨ufstand. Gyn¨akologie 3/2005
58.刘春梅,徐苓.围绝经期妇女预防性卵巢切除意义的探讨[,].中国实用妇科与产科,2005,21(4):250—252
59.Wuttke W, Gorkow C, Seidlová-Wuttke D Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. Menopause 2006 Mar-Apr;13(2):185-96.
60.胡光民张祖忘刘艳王海颖中国明许浩黑升麻提取物对去势大鼠下丘脑一垂体一性腺轴的影响中国中医药科技2009年7月第16卷第4期
1.Mahady,G. B. IS black cohosh estrogenic? Nutr.Rev .2003,61,181-186
2.Cqrpenter,J.S.State of the science: hot flash and cancer .Part 2:management andfuture diretions.Oncol Nurs.Forum 2005,32,969-978.
3.Heckbert SR, Kaolan RC, Weiss NS, et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001;16:709.
4.Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605.
5.Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304.
6.Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologicalstudies of 52,705 women with breast cancer and 108,411 women without breast cancer.Lancet 1997;350:1047.
7.Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589.
8.Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.JAMA 2000;283:485.
9.Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of U.S. women. JAMA 2001;285:1460.
10.Molla MD, Hidalgo-Mora JJ, Soteras M G Phytotherapy as alternative to hormone replacement therapy. 2011 Jan 1;3:191-204.
11.贡联兵缓解围绝经期综合症的植物药-黑升麻的异丙醇提取物(Remifemin)临床应用与评价2010 08 1672-2124
12.Osmers R,Friede M,Liske E,Efficacy ane safety of isopropanol black cohosh extract for climateric systoms [ J] ObstetG ynecol, 2005, 105( 5 ) : 1074-1083
13.Volker Viereck,Gunter Emons ane Wolfgang Wuttke Black cohosh:just another phytoestrogen? Trends Endocrinol Metab.2005 Jul;16(5):214-21
14.Benjamin Kligler,Black cohosh.Complementary and ahemative[J] Benjamin Kligler,Black cohosh. Medicine,2003.68(1):114
15.Bone K TownsendLetter for Doctors and Patients, Phytotherapy review and commentary 2006 .July,pp 66–70
16.Kretzschmar G, Nisslein T, Zierau O, Vollmer G (2005) Noestrogen-like effects of anisopropanolic extract o f Rhizoma Cimicifugae racemosae on uterus and vena cava of rats after
17day treatment. J Steroid Biochem Mol Biol 97:271–277
17.Wenpei Bai,Hans-Heinrich Henneicke-von Zepelin,Shuyu Wang,Shur.Efficacy and tolerability of a medicinal product congtaining an isopropanolic black cohosh extract in Chinese women with menoparusal symptoms: A randomized ,double blind ,parallel-controlled study versus tibolone Maturitas 58 (2007) 31-41
18.Liske E, H?nggi W, Henneicke-von Zepelin HH, Boblitz N, Wüstenberg P, Rahlfs VW。Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002 Mar;11(2):163-74.
19.Bodinet C, Freudensten J Influence of marketed herbal menopause preparations on MCF-7 cell proliferation{J} Menpausel JNAMS 2004,11 (3) :281-289
20.曹泽毅中华妇产科学临床版516-519
21.Osmers R,Friede M,Liske E,Schnitker J,Frendenstein J,Henneicke-von,Zeoelin HH.Efficacy and safety of isopropanolic black cohosh extract for climateric symptoms .Obstet Gynecol .2005 May:105(5 pt1)1074-83
22.Roddella E Nappi Barbara Malavasi Benedetta Brundu Eefficacy of Cinicifuga racemosa on climateric complaints:A randomized study versus low-dose transdermal estradiol Gynecological Endocrinology ,January 2005;20(1):30_35
23.Vermes G, Bánhidy F, Acs N.The effects of remifemin on subjective symptoms of menopause.Adv Ther 2005 Mar-Apr;22(2):148-54.
24.Gerardo HM, Salvatore P. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer[ J ]. Maturitas, 2003, 44 (1) :59.
25.Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer[ J ]. J Clin Oncol, 2001, 19: 2739.
26.Pockaj BA, Loprinzi CL, Sloan JA, Novotny PJ, Barton DL,Hagenmaier A, Zhang H, Lambert GH, Reeser KA, Wisbey JA (2004) Pilot evaluation of black cohosh for the treatment of hotflashes in women. Cancer Invest 22:515–521
27.Uebelhack R,Blohmer JU,Graubaum HJ,et al.Black cohosh and St.John’s Wort for Climacteric complaints.Obstet Gynecol ,2006,107(2):247-255
28.Burdette JE,Liu J,Chen SN,et al. Black cohosh actsas a mixed competitive ligand and partial agonist of theserotonin receptor[J ]. J Agric Food Chem,2003,51(19) :5661
29.Benjamin Kligler,Black cohosh.Complementary and ahemative[J] Benjamin Kligler,Black cohosh. Medicine,2003.68(1):114.
30.Wuttke W, Gorkow C, Seidlová-Wuttke D Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. Menopause 2006 Mar-Apr;13(2):185-96.
31.Viereck V, Gründker C, Friess SC, Frosch KH, Raddatz D, Schoppet M, Nisslein T, Emons G, Hofbauer LC.Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts.J Bone Mines Res 2005 Nov;20(11):2036-43.
32.Einbond LS, Shimizu M, Xiao D, et al. Growth inhibitory activity of extractand purified components of black cohosh on human breast cancer cells. BreastCancer Res Treat 2004;83:221-231. Bibliographic Links Library Holdings
33.Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. Cimicifugaracemosa extract inhibits proliferation of estrogen receptor-positive andnegative human breast carcinoma cell lines by induction of apoptosis. BreastCancer Res Treat 2004;84:151-160. Bibliographic Links Library Holdings
34.Al-Akoum M, Dodin S, Akoum A.Synergistic cytotoxic effects of tamoxifen and black cohosh on MCF-7 and MDA-MB-231 human breast cancer cells: an in vitro study. 2007 Nov;85(11):1153-9
35.Hirschberg AL, Edlund M, Svane G, Azavedo E, Skoog L, von Schoultz B An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. 2007 Jan-Feb;14(1):89-96
36.Zepelin HH, Meden H, Kostev K, Schr?der-Bernhardi D, Stammwitz U, Becher HIsopropanolic black cohosh extract and recurrence-free survival after breast cancer. 2007 Mar;45(3):143-54.
37.Raus K, Brucker C, Gorkow C, Wuttke W First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 105 Department of Obstetrics and Gynecology, Charles University Teaching Hospital, Prague, Czech Repub2006 Jul-Aug;13(4):678-91
38.Alves DL, Lima SM, da Silva CR, Galv?o MA, Shanaider A, de Almeida Prado RA, Aoki T.Effects of Trifolium pratense and Cimicifuga racemosa on the endometrium of Wistar rats. 2008 Dec 20;61(4):364-70. Epub 2008 Dec 17.
39.胡光民,刘艳.黑升麻对去卵巢大鼠子宫内膜及血清雌激素水平的影响.中国中医药杂志,2008,6(5):26-28
40.Spangler L Newton KM ,Grothaus LC, Reed SD,Ehrlich K,Lacroix AZ The effets of black cohosh therpies on lipids ,fibrinogen,glucose and insulin.Maturilas.2007 Jun 20:57(2):195-204
41.Teschke R, Bahre R, Genthner A, Fuchs J, Schmidt-Taenzer W, Wolff A. Suspected black cohosh hepatotoxicity--challenges and pitfalls of causality assessment Maturitas. 2009 Aug 20;63(4):302-14. Epub 2009 Jul 7.
42.Naser B, Schnitker J, Minkin MJ, de Arriba SG, Nolte KU, Osmers R. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. 2011 Jan 11.
2.Cqrpenter,J.S.State of the science: hot flash and cancer .Part 2:management andfuture diretions.Oncol Nurs.Forum 2005,32,969-978.
3.Heckbert SR, Kaolan RC, Weiss NS, et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001;16:709.
4.Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605.
5.Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304.
6.Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologicalstudies of 52,705 women with breast cancer and 108,411 women without breast cancer.Lancet 1997;350:1047.
7.Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589.
8.Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.JAMA 2000;283:485.
9.Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of U.S. women. JAMA 2001;285:1460.
10.Blumenthal M, Busse WR, Goldberg A, et al., eds. Klein S, Rister RS, translators. German Commission E monographs: Therapeutic monographs on medicinal plants for human use. Austin, TX: American Botanical Council, 1998.
11.Schildge E. Beitrag zur Behandlung von pr?menstruellen und klimakterischen Verstimmungs-und Depressionszust?nden. Ringelh Biol Umsch 1964;19:18.
12.Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin HH. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol.2005;105:1074-83. [PMID: 15863547] 125I-labeled antipyrine
13.Nappia RE,Malavasi B,Brundu B,Facchinetti F,Efficacy of cimicifuga racemosa on climacteric complaint :a randomized study versus low-dose transdermal estradial.Gynecol Endocrinol 2005;20(1):30-35
14.Vermes G, Bánhidy F, Acs N.The effects of remifemin on subjective symptoms of menopause.Adv Ther 2005 Mar-Apr;22(2):148-54.
15.Molla MD, Hidalgo-Mora JJ, Soteras M G Phytotherapy as alternative to hormone replacement therapy. 2011 Jan 1;3:191-204.
16.wenpei Bai,Hans-Heinrich Henneicke-von Zepelin,Shuyu Wang,Shur.Efficacy and tolerability of a medicinal product congtaining an isopropanolic black cohosh extract in Chinese women with menoparusal symptoms: A randomized ,double blind ,parallel-controlled study versus tibolone Maturitas 58 (2007) 31-41
17.acobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739–45.
18.Liske E, H?nggi W, Henneicke-von Zepelin HH, Boblitz N, Wüstenberg P, Rahlfs VW。Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002 Mar;11(2):163-74.
19.Lehmann-Willenbrock E, Riedel HH. (Clinical and endocrinological examinations concerning therapy of climacteric symptoms following hysterectomy with remaining ovaries). Zentralbl Gynakol 1988;110:611.
20.Einer-Jensen N, Zhao J, Andersen KP, Kristoffersen K. Cimicifuga andMelbrosia lack oestrogenic effects in mice and rats. Maturitas 1996;25:149-153.Bibliographic Links Library Holdings
21.Freudenstein J, Dasenbrock C, Nisslein T. Lack of promotion of estrogen-dependentmammary gland tumors in vivo by an isopropanolic Cimicifuga racemosa extract.Cancer Res 2002;62:3448-3452. Bibliographic Links Library Holdings
22.Herbertson A,Aubin J E,Cell sorting enriches osteogenic populations in rat bone marrow stromal cell cultures[J] Bone,1997,21(6):491-500
23.Zepelin HH, Meden H, Kostev K, Schr?der-Bernhardi D, Stammwitz U, Becher HIsopropanolic black cohosh extract and recurrence-free survival after breast cancer. 2007 Mar;45(3):143-54.
24.Geller SE ,Studee L Botanical and dietary supplements for menopausal symptom: what work ,what dose not.J Womens Health 2005;14:634-649
25.Osmers R Kraft K.Phytotherapy in menopausal symptoms.Pharm Unserer Zeit 2004,33:384-381.
26.Liske E, H?nggi W, Henneicke-von Zepelin HH, Boblitz N, Wüstenberg P, Rahlfs VW。Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002 Mar;11(2):163-74.
27.O'Connor K, Belanger L, Marchand A, et al. Psychological distress andadaptational problems associated with discontinuation of benzodiazepines. AddictBehav. 1999;24:537-541.Bibliographic Links Library Holdings
28.Freudenstein J, Bodinet C. Influence of an isopropanolicaqueous extract of Cimicifuga racemosa rhizomaon the proliferation of MCF-7 cells. Abstractband: 23rd International LOF-Symposium on“Phyto-Oestrogens.”Workshop of the Society for MedicinalPlant Research, Gent, 1999.
29.Nesselhut T, Liske E. Pharmacological measures in postmenopausal women with an isopropanolic aqueousextract of Cimicifuga racemosa rhizoma. Abstract10th Annual Meeting NAMS, New York, September1999.
30.Kalantaridou SN,Davis SR,Calis LA. Hormone therapy in women.In: DiPiro JT,Talbert RL,Yee GC,et al.Pharmacotherapy:a pathophysiologic approach Sixth Edition.McGraw-Hill. 2005,PP: 1493 -1513.[25]Bai W,Henneicke-von Zepelin H-H,Wan
31.Gabort Vermes,MD.Ferenc banhidy,MD,PHD. Nandor Acs,MD,PHD.The effects of Remifemin on subjective symptoms of menopause Advance in therapy 2005;148-154
32.Nelson HD,Vesco KK,Haney E,Fu R ,Nedrow A, Miller J,Nicolaides C,Walker M,Humphery L (2006)Nonhormonal therapies for menopausal hot flash :systematic review and metanalysis .JAMA 295:2057-2071
33.Gerardo HM, Salvatore P. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer[ J ]. Maturitas, 2003, 44 (1) :59.
34.Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer[ J ]. J Clin Oncol, 2001, 19: 2739.
35.Pockaj BA, Loprinzi CL, Sloan JA, Novotny PJ, Barton DL,Hagenmaier A, Zhang H, Lambert GH, Reeser KA, Wisbey JA (2004) Pilot evaluation of black cohosh for the treatment of hotflashes in women. Cancer Invest 22:515–521
36.Burdette JE,Liu J,Chen SN. Black cohosh acts as a mixed competitiveligand and partial agonist of the serotonin receptor [J].Agricultural and Food Chemistry,2003,51( 19) : 5661 - 5670.
37.Maoz B, Shiber A, Lazer S, et al. Prevalence of psychological distress amongpostmenopausal women attending a menopausal clinic and the effect of hormone replacement therapy on their mental state. Menopause. 1994;1:137-141.
38.Amsterdam JD, Garcia-Espana F, Goodman D, et al. Breast enlargement duringchronic SSRI therapy. J Affect Disord. 1997;46:151-156.
39.O'Connor K, Belanger L, Marchand A, et al. Psychological distress andadaptational problems associated with discontinuation of benzodiazepines. AddictBehav. 1999;24:537-541. Bibliographic Links Library Holdings
40.Soares CN, Murray BJ.Sleep disorders in women: clinical evidence and treatment strategies. Psychiatr Clin North Am. 2006 Dec;29(4):1095-113; abstract xi.
41.Borrelli,F.Ernst,E. Black cohosh(cimicifuga racemosa)for menopausal symptom:a systematic review of its efficacy .Pharmacol Res.2008,58,8-14
42.Lehmann-Willenbrock E, Riedel HH. (Clinical and endocrinological examinations concerning therapy of climacteric symptoms following hysterectomy with remaining ovaries). Zentralbl Gynakol 1988;110:611.
43.Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. 2010 Mar;17(2):426-4
44.Hirschberg AL, Edlund M, Svane G, Azavedo E, Skoog L, von Schoultz B An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. 2007 Jan-Feb;14(1):89-96.
45.Freudenstein J, Dasenbrock C, Nisslein TLack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic Cimicifuga racemosa extract. Cancer Res. 2002 Jun 15;62(12):3448-52.
46.胡玉红不同术式对雌兔内分泌和骨代谢的影响中国比较医学杂志2007,7
47.徐丽丽杨乃龙体外诱导人骨髓间充质干细胞向成骨细胞的分化2008
48.刘忠厚.骨质疏松学[M].北京:科技出版社,1998.
49.陶敏芳等,双侧卵巢切除对绝经期妇女骨密度及身体成分的影响上海交通大学学报2010 (9)
50.Cos,P.et al.(2003)Phytoestrogens :recent developments.PLANTA Med.69,589-599
51.Schildge E. Beitrag zur Behandlung von pr?menstruellen und klimakterischen Verstimmungs-und Depressionszust?nden. Ringelh Biol Umsch 1964;19:18
52.Whiting PW,Clouston A,Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis [J]. Med J Aus,2002,177(8):432-435.
53.Naser B, Schnitker J, Minkin MJ, de Arriba SG, Nolte KU, Osmers R. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. 2011 Jan 11.
54.Pockaj B, Gallagher J, Loprinzi C, Stella P, Barton D, Sloan J, et al. Phase III double-blind, randomized, placebo-controlled clinical crossover trial of black cohosh in the management of hot flashes: NCCTG trial N01CC. J Clin Oncol 2006;24:2836–41.
55.acobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739–45.
56.Frei-Kleiner S, SchaffnerW, RahlfsVW, Bodmer C, Birkh¨auser M. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial.Maturitas 2005;51:397–404.
57.Bischoff M. Wechseljahre: Pflanzliche Alternativen auf dem Pr¨ufstand. Gyn¨akologie 3/2005
58.刘春梅,徐苓.围绝经期妇女预防性卵巢切除意义的探讨[,].中国实用妇科与产科,2005,21(4):250—252
59.Wuttke W, Gorkow C, Seidlová-Wuttke D Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. Menopause 2006 Mar-Apr;13(2):185-96.
60.胡光民张祖忘刘艳王海颖中国明许浩黑升麻提取物对去势大鼠下丘脑一垂体一性腺轴的影响中国中医药科技2009年7月第16卷第4期
1.Mahady,G. B. IS black cohosh estrogenic? Nutr.Rev .2003,61,181-186
2.Cqrpenter,J.S.State of the science: hot flash and cancer .Part 2:management andfuture diretions.Oncol Nurs.Forum 2005,32,969-978.
3.Heckbert SR, Kaolan RC, Weiss NS, et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001;16:709.
4.Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605.
5.Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304.
6.Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologicalstudies of 52,705 women with breast cancer and 108,411 women without breast cancer.Lancet 1997;350:1047.
7.Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589.
8.Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.JAMA 2000;283:485.
9.Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of U.S. women. JAMA 2001;285:1460.
10.Molla MD, Hidalgo-Mora JJ, Soteras M G Phytotherapy as alternative to hormone replacement therapy. 2011 Jan 1;3:191-204.
11.贡联兵缓解围绝经期综合症的植物药-黑升麻的异丙醇提取物(Remifemin)临床应用与评价2010 08 1672-2124
12.Osmers R,Friede M,Liske E,Efficacy ane safety of isopropanol black cohosh extract for climateric systoms [ J] ObstetG ynecol, 2005, 105( 5 ) : 1074-1083
13.Volker Viereck,Gunter Emons ane Wolfgang Wuttke Black cohosh:just another phytoestrogen? Trends Endocrinol Metab.2005 Jul;16(5):214-21
14.Benjamin Kligler,Black cohosh.Complementary and ahemative[J] Benjamin Kligler,Black cohosh. Medicine,2003.68(1):114
15.Bone K TownsendLetter for Doctors and Patients, Phytotherapy review and commentary 2006 .July,pp 66–70
16.Kretzschmar G, Nisslein T, Zierau O, Vollmer G (2005) Noestrogen-like effects of anisopropanolic extract o f Rhizoma Cimicifugae racemosae on uterus and vena cava of rats after
17day treatment. J Steroid Biochem Mol Biol 97:271–277
17.Wenpei Bai,Hans-Heinrich Henneicke-von Zepelin,Shuyu Wang,Shur.Efficacy and tolerability of a medicinal product congtaining an isopropanolic black cohosh extract in Chinese women with menoparusal symptoms: A randomized ,double blind ,parallel-controlled study versus tibolone Maturitas 58 (2007) 31-41
18.Liske E, H?nggi W, Henneicke-von Zepelin HH, Boblitz N, Wüstenberg P, Rahlfs VW。Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002 Mar;11(2):163-74.
19.Bodinet C, Freudensten J Influence of marketed herbal menopause preparations on MCF-7 cell proliferation{J} Menpausel JNAMS 2004,11 (3) :281-289
20.曹泽毅中华妇产科学临床版516-519
21.Osmers R,Friede M,Liske E,Schnitker J,Frendenstein J,Henneicke-von,Zeoelin HH.Efficacy and safety of isopropanolic black cohosh extract for climateric symptoms .Obstet Gynecol .2005 May:105(5 pt1)1074-83
22.Roddella E Nappi Barbara Malavasi Benedetta Brundu Eefficacy of Cinicifuga racemosa on climateric complaints:A randomized study versus low-dose transdermal estradiol Gynecological Endocrinology ,January 2005;20(1):30_35
23.Vermes G, Bánhidy F, Acs N.The effects of remifemin on subjective symptoms of menopause.Adv Ther 2005 Mar-Apr;22(2):148-54.
24.Gerardo HM, Salvatore P. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer[ J ]. Maturitas, 2003, 44 (1) :59.
25.Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer[ J ]. J Clin Oncol, 2001, 19: 2739.
26.Pockaj BA, Loprinzi CL, Sloan JA, Novotny PJ, Barton DL,Hagenmaier A, Zhang H, Lambert GH, Reeser KA, Wisbey JA (2004) Pilot evaluation of black cohosh for the treatment of hotflashes in women. Cancer Invest 22:515–521
27.Uebelhack R,Blohmer JU,Graubaum HJ,et al.Black cohosh and St.John’s Wort for Climacteric complaints.Obstet Gynecol ,2006,107(2):247-255
28.Burdette JE,Liu J,Chen SN,et al. Black cohosh actsas a mixed competitive ligand and partial agonist of theserotonin receptor[J ]. J Agric Food Chem,2003,51(19) :5661
29.Benjamin Kligler,Black cohosh.Complementary and ahemative[J] Benjamin Kligler,Black cohosh. Medicine,2003.68(1):114.
30.Wuttke W, Gorkow C, Seidlová-Wuttke D Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. Menopause 2006 Mar-Apr;13(2):185-96.
31.Viereck V, Gründker C, Friess SC, Frosch KH, Raddatz D, Schoppet M, Nisslein T, Emons G, Hofbauer LC.Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts.J Bone Mines Res 2005 Nov;20(11):2036-43.
32.Einbond LS, Shimizu M, Xiao D, et al. Growth inhibitory activity of extractand purified components of black cohosh on human breast cancer cells. BreastCancer Res Treat 2004;83:221-231. Bibliographic Links Library Holdings
33.Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. Cimicifugaracemosa extract inhibits proliferation of estrogen receptor-positive andnegative human breast carcinoma cell lines by induction of apoptosis. BreastCancer Res Treat 2004;84:151-160. Bibliographic Links Library Holdings
34.Al-Akoum M, Dodin S, Akoum A.Synergistic cytotoxic effects of tamoxifen and black cohosh on MCF-7 and MDA-MB-231 human breast cancer cells: an in vitro study. 2007 Nov;85(11):1153-9
35.Hirschberg AL, Edlund M, Svane G, Azavedo E, Skoog L, von Schoultz B An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. 2007 Jan-Feb;14(1):89-96
36.Zepelin HH, Meden H, Kostev K, Schr?der-Bernhardi D, Stammwitz U, Becher HIsopropanolic black cohosh extract and recurrence-free survival after breast cancer. 2007 Mar;45(3):143-54.
37.Raus K, Brucker C, Gorkow C, Wuttke W First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 105 Department of Obstetrics and Gynecology, Charles University Teaching Hospital, Prague, Czech Repub2006 Jul-Aug;13(4):678-91
38.Alves DL, Lima SM, da Silva CR, Galv?o MA, Shanaider A, de Almeida Prado RA, Aoki T.Effects of Trifolium pratense and Cimicifuga racemosa on the endometrium of Wistar rats. 2008 Dec 20;61(4):364-70. Epub 2008 Dec 17.
39.胡光民,刘艳.黑升麻对去卵巢大鼠子宫内膜及血清雌激素水平的影响.中国中医药杂志,2008,6(5):26-28
40.Spangler L Newton KM ,Grothaus LC, Reed SD,Ehrlich K,Lacroix AZ The effets of black cohosh therpies on lipids ,fibrinogen,glucose and insulin.Maturilas.2007 Jun 20:57(2):195-204
41.Teschke R, Bahre R, Genthner A, Fuchs J, Schmidt-Taenzer W, Wolff A. Suspected black cohosh hepatotoxicity--challenges and pitfalls of causality assessment Maturitas. 2009 Aug 20;63(4):302-14. Epub 2009 Jul 7.
42.Naser B, Schnitker J, Minkin MJ, de Arriba SG, Nolte KU, Osmers R. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. 2011 Jan 11.